Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
EUROPEAN COMMISSION, DIRECTORATE-GENERAL FOR COMPETITION (COMP) has floated a tender for Ex Post Evaluation: Eu Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects. The project location is Belgium and the tender is closing on 18 Oct 2021. The tender notice number is 398626-2021, while the TOT Ref Number is 55974427. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : Belgium
Summary : Ex Post Evaluation: Eu Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects
Deadline : 18 Oct 2021
Other Information
Notice Type : Tender
TOT Ref.No.: 55974427
Document Ref. No. : 398626-2021
Financier : European Commission
Purchaser Ownership : -
Tender Value : EUR 500000.00
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Document Type : Contract notice
Title : Ex Post Evaluation: EU Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects
Reference Number : COMP/2021/OP/0002
Contract Type : Services
Estimated Value : 500000.00 - EUR
Description : Empirical research by Cunningham et al. (2021) suggests that in the pharmaceutical industry a considerable number of acquisitions might have as their object or effect the discontinuation of overlapping drug R&D projects to the detriment of innovation competition and ultimately consumers. Such acquisitions are commonly referred to as ‘killer acquisitions-. The study aims to determine what are the typical features of such killer acquisitions and obtain evidence on the prevalence of such acquisitions, as this would allow the Commission to determine which transactions in the pharmaceutical industry deserve closer scrutiny. A second objective of the study is to conduct ex post evaluations of selected past merger decisions. These case studies aim to assess whether in the concentrations notified to and examined by the Commission under the EU Merger Regulation, the Commission correctly anticipated the risks of possible discontinuations of competing lines of drug R&D projects.
79311410 - Economic impact assessment
79310000 - Market research services
79419000 - Evaluation consultancy services
33600000 - Ph...
Documents
Procurement Documents for Belgium
Access a comprehensive library of standard procurement documents specific to Belgium. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in Belgium
Want To Bid in This Tender?
Get Local Agent Support in Belgium and 60 More Countries.
View Tenders By
Sign in with Google